News

30 July 2026

SOHO Global Health Reports Strong EBITDA Growth of 35.7% Year-on-Year in 1H-2026

Key Highlights                      

- SOHO Group recorded a 3.7% year-on-year (YoY) increase in Net Revenues to IDR5.36 trillion and a 35.7% YoY growth in EBITDA to IDR489 billion, accompanied by margin expansion, primarily driven by the strong performance of its Consumer Health and Alliance businesses, as well as continued operational efficiency initiatives.

- The Company remains focused on driving sustainable growth through digital marketing investments, new product launches, as well as the addition and strengthening of strategic partnerships.

Jakarta, 30 July 2026 – PT SOHO Global Health Tbk (IDX: SOHO) and its subsidiaries ("SOHO Group" or the "Company") today announced its unaudited consolidated financial results for the first six months ended 30 June 2026. The Company delivered strong financial performance, with EBITDA increasing by 35.7% YoY to IDR489 billion, while Net Revenues grew 3.7% YoY to IDR5.36 trillion. Gross profit margin and EBITDA margin also improved, supported by a more favourable business mix, with Consumer Health and Alliance businesses serving as key growth drivers, alongside continued operational discipline. Net profit rose 28.4% YoY to IDR373 billion, reflecting strong operating performance and a slight decline from non-operating items. This performance was primarily driven by the Consumer Health and Alliance businesses, which also contributed to market share gains. Looking ahead, SOHO Group remains committed to creating sustainable long-term value through digital marketing investment, new product development, strategic partnerships, and continued operational excellence.

“During the first half of 2026, the Company delivered solid financial performance, achieving industry leading double-digit EBITDA growth in line with our targets, accompanied by margin expansion that reflects the resilience of our integrated business model amid a dynamic market environment. This achievement was supported by the continued growth of our Consumer Health business, particularly through digital channels, the strengthening of strategic partnerships within our Alliance business, and disciplined cost management, which collectively enhanced our profitability. Amid ongoing market uncertainties, we will remain focused on strengthening our business fundamentals through both organic and inorganic growth, supported by continuous innovation and strategic partnerships, to deliver sustainable growth and create long-term value for our shareholders,” said Piero Brambati, CFO and COO of PT SOHO Global Health Tbk.

(Expressed in IDR Million)

Consumer Health Business – Net revenues increased 32.9% YoY, primarily driven by strong growth in the children's and adults' vitamins and supplements categories, particularly through online sales channels. Gross profit margin and EBITDA margin improved, supported by a favourable product mix, operating leverage and higher capacity utilization. SOHO Group will continue to strengthen its digital marketing investments and expand its new product pipeline, particularly in the beauty and preventive healthcare categories.

Alliance Business – Net revenues grew 118.4% YoY, driven by the commencement of the strategic partnership with Johnson & Johnson in early 2026, as well as continued growth in several categories. Gross profit margin and EBITDA margin declined due to changes in the partnership mix, reflecting the different margin profile of the Johnson & Johnson business. Looking ahead, SOHO Group will focus on adding and strengthening strategic partnerships as well as expanding its curated portfolio of RX own brands.

Distribution Business – Net revenues declined 2.7% YoY following the loss of several principals, while the Company is actively securing replacement partnerships. Gross profit margin improved, supported by a more favourable principal mix. Going forward, SOHO Group will continue to selectively evaluate and strengthen its principal portfolio with a focus on higher-margin partnerships, while maintaining operational cost efficiency and optimizing working capital management.

The Company continues to maintain a strong net cash position and healthy working capital to support business sustainability, including effective supply chain and inventory management. The Company also remains committed to maximizing shareholder value and returning excess cash to shareholders through its paid dividend distribution of IDR921 billion from the 2025 net profit, which was paid in 2026. The Company has allocated a capital expenditure budget of up to IDR50–55 billion for this year.

The Company maintains its 2026 outlook, targeting mid to high single-digit Net Revenues growth, strong double-digit EBITDA growth, and a ~50% dividend payout ratio, subject to cash flow generation and working capital requirements.

For more information, please contact:

Syeren Amanda

Head of Investor Relations

syeren.amanda@sohoglobalhealth.com

or

corporate.secretary@sohoglobalhealth.com

About SOHO Global Health

SOHO Global Health is a leading healthcare company with a more than 80-year history and core competencies in the areas of natural/herbal health care products and services.  Our more than 30 group brands range from best seller immunomodulator brands like Imboost, hepatoprotector product like Curcuma FCT, health supplement Asthin Force, Lotion/Beauty Noroid, to leading kids multivitamin brands like Curcuma Plus and Fitkom. Guided by our corporate purpose “We hold the care of human life as our highest priority and thereby Glorify God” we help to prevent and treat diseases, promotes healthy lifestyle and the well-being of the community.

SOHO Global Health offers a unique and best-in-class platform in branding, sales & marketing, manufacturing and distribution to support future growth in the Indonesian healthcare market. Supported by over 2,300 employees, SGH brand stands for trust, reliability and quality among healthcare professionals, patients and customers. We have a strong commitment to sustainability and create long term value. The patient is and will remain at the core of what we do, the reason we come to work every day.